Louisiana HB 403: INSURANCE: Authorizes substitution of certain biosimilar biological products relative to step therapy or fail first protocols

Status: Signed by the Governor. Becomes Act No. 125. (as of 2023-06-06)

State: Louisiana · Session: 2023 · Bill: HB 403

Sponsors: Chad Brown

View Louisiana HB 403 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.